Edwards says PARTNER 3 data show continued low rates of all-cause mortality

Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. “These data, which represent the longest clinical follow-up for a low surgical risk cohort of transcatheter aortic valve replacement – TAVR – patients, were presented during a late-breaking clinical trials session at the 35th Transcatheter Cardiovascular Therapeutics, the annual scientific symposium of the Cardiovascular Research Foundation, and published simultaneously in The New England Journal of Medicine,” the company stated.